Paradigm Biopharmaceuticals (ASX:PAR) Other Financing: A$-0.05 Mil (TTM As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.17
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Other Financing?

Paradigm Biopharmaceuticals ASX:PAR 28 Other Financing is A$-0.05 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's Other Financing for the six months ended in Dec. 2025 was A$0.01 Mil.

Paradigm Biopharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.05 Mil.

Paradigm Biopharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Other Financing Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.14 -0.10 -0.10 -0.13

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.05 -0.06 -0.07 0.01
ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of A$-0.05 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Other Financing of A$-0.05 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Other Financing too high?
Paradigm Biopharmaceuticals' current Other Financing is A$-0.05 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Other Financing compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Other Financing of A$-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Other Financing is A$-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Other Financing of A$-0.05 Mil. The current Other Financing is A$-0.05 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Other Financing is A$-0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.17
Price